Reading MXCT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MXCT free→Reading MXCT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MXCT free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been fairly steady, but the capital stance is capital unfriendly, and risk is high. The sector backdrop is a headwind, and compared with sector peers, MXCT is above typical. Peer multiples imply a price about 27% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while recent financials are weak. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $1.14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $1.12 MXCT trades at 3× p/s, in line with its 3× p/s peer median. Our $1.57 fair value reflects that, medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 28% below a flat-multiple fair value, below our forecast of about -8%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.72x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
5 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-0.09. 0 raised, 1 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 71% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$274.
How much price usually moves either way.
On a bad day, this stock has moved -$680.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,098.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'fair' to 'inexpensive'.
Valuation changed. It rose from fair to inexpensive. Risk remained high. The sector backdrop was a headwind.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for MXCT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 12, 2026, MaxCyte, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securit…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2024-Q3, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
MXCT MaxCyte, Inc. | Above typical Show detailsSector percentile: 72 of 100 | inexpensive | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 93 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Typical Show detailsSector percentile: 54 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
MaxCyte aims to achieve its 2026 revenue guidance of $30-32 million, with core revenue of $25-27 million and SPL Program-related revenue of $5 million.
Stated in 2 of last 2 quarters. Revenue grew from $7.3M in 2025-Q4 to $9.65M in 2026-Q1, indicating progress towards the 2026 revenue guidance of $30-32 million. The trajectory shows delivering progress towards the target.
“Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million.”
“MaxCyte is providing initial revenue guidance for full year 2026... Full year revenue expected to be $30 million to $32 million.”
MaxCyte aims to maintain a cash, cash equivalents, and investments position of at least $155 million by year-end 2025.
Newly stated in 2025-Q3. The financials do not provide a direct update on the cash position, but maintaining a cash position of at least $155 million remains a stated goal. Limited substantive delivery evidence this quarter.
“Expects year-end cash, cash equivalents, and investments to be at least $155 million.”
MaxCyte needs to address the Nasdaq minimum bid price requirement to avoid delisting.
Newly stated in 2026-Q1. The company received a notice from Nasdaq for failing to meet the minimum bid price requirement. This regulatory issue requires immediate attention, but no resolution has been reported yet.
“Received notice from Nasdaq for not complying with the minimum bid price requirement.”
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Parmeet Ahuja as Chief Financial Officer On March 23, 2026, the Board of Directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) appointed Parmeet Ahuja as the Company’s Chief Financial Officer, effective March 30, 2026. Mr. Ahuja will also serve as the Company’s principal accounting officer. Mr. Ahuja succeeds Douglas Swirsky,…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On March 16, 2026, MaxCyte, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasda…
Results of Operations and Financial Condition. On March 24, 2026, MaxCyte, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18…
and Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any genera…